Latest Schedule 13G passive stakes

MEITAV INVESTMENT HOUSE LTD has updated its beneficial ownership filing for Nayax Ltd., reporting a 5.00% stake in the company's ordinary shares.

JRJ Investor 1 LP and associated entities have filed an amendment to Schedule 13G, reporting zero shares beneficially owned in Marex Group plc as of June 30, 2026.

Marex Group plc filing confirms zero beneficial ownership of common stock by MASP Investor Limited Partnership, Forty Two Point Two Acquisition Limited, and BXR Group Holdings Limited as of June 30, 2026.

An amendment to Schedule 13G has been filed for Valaris Limited, detailing changes in beneficial ownership by Giovanni Agnelli B.V., Exor N.V., Lingotto Investment Management (UK) Limited, and Lingotto Investment Management LLP.

Lingotto Investment Management LLP, along with affiliated entities, has reported a 7.12% beneficial ownership of VEON Ltd. ADSs, with no immediate intent to influence control.

Prosight Management, LP and affiliated entities have filed a Schedule 13G, reporting a combined beneficial ownership of 2.4% of OnKure Therapeutics, Inc. Class A Common Stock.

Thomas Keefe has filed an amendment to Schedule 13G, reporting zero beneficial ownership of Hub Cyber Security Ltd. ordinary shares as of June 30, 2026.

A Schedule 13G filing details beneficial ownership changes for Allogene Therapeutics, Inc. by key individuals and entities.

Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. have filed an amended Schedule 13G, confirming their beneficial ownership of 557,800 ordinary shares, representing 12.41% of Columbus Acquisition Corp.

Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. have amended their Schedule 13G filing to report beneficial ownership of 557,800 ordinary shares, representing 7.02% of Columbus Acquisition Corp.

Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. have amended their Schedule 13G filing for Graf Global Corp., reporting a combined beneficial ownership of 12.97% of Class A common stock.

Harraden Circle Investments, LLC and Frederick V. Fortmiller, Jr. have amended their Schedule 13G filing, reporting a reduced beneficial ownership of Graf Global Corp. Class A shares.

Logos Global Management LP and affiliated entities have reported an amendment to their Schedule 13G filing, detailing changes in their beneficial ownership of Yarrow Bioscience, Inc. common stock.

White Lion Capital LLC has reported beneficial ownership of 5.0% of Akari Therapeutics Plc's ordinary shares, represented by American Depositary Shares, as of August 7, 2026.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 10.5% of Nebius Group N.V.'s Class A Ordinary Shares.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 10.5% of Nebius Group N.V.'s Class A Ordinary Shares.

Thrivent Financial for Lutherans has reported a significant beneficial ownership of 22.4% in Gloo Holdings, Inc., holding 4,655,000 shares of Class A Common Stock.

Gagnon Securities LLC, Gagnon Advisors, LLC, and Neil Gagnon have updated their beneficial ownership filings for CareDx, Inc., reporting a combined stake.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 7.2% of Nebius Group N.V.'s Class A Ordinary Shares.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 7.2% of Nebius Group N.V.'s Class A Ordinary Shares.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a complete divestment of their beneficial ownership in XOMA Royalty Corp, holding 0.0% of the class of securities.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a complete divestment of their beneficial ownership in XOMA Royalty Corp, holding 0.0% of the class of securities.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed a Schedule 13G detailing their beneficial ownership of XOMA Royalty Corp. common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed a Schedule 13G detailing their beneficial ownership of XOMA Royalty Corp. common stock.

Alumni Capital LP, along with its general partner and controlling person, has reported beneficial ownership of 9.99% of INVO Fertility, Inc. common stock, primarily through an Any Market Purchase Agreement.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G, reporting beneficial ownership of 11.9% of BioVie Inc.'s Class A Common Stock.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G, reporting beneficial ownership of 11.9% of BioVie Inc.'s Class A Common Stock.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed beneficial ownership of 8.0% of BioVie Inc.'s Class A Common Stock as of June 30, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed beneficial ownership of 8.0% of BioVie Inc.'s Class A Common Stock as of June 30, 2026.

Askeladden Capital Management LLC and Samir Patel have filed a Schedule 13G amendment indicating they no longer beneficially own any shares of INTEST CORP common stock.